---
title: "Top Intellia Executive Quietly Unloads a Chunk of Company Stock"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291876769.md"
description: "Intellia Therapeutics Vice President and Chief Accounting Officer Michael P. Dube sold 2,641 shares for $44,315 on July 6, 2026. TipRanks' AI Analyst Spark rates NTLA stock as Neutral, citing weak financial performance offset by strong Phase 3 data and a positive technical backdrop. The company currently has a market cap of $2.45B with a 'Buy' technical sentiment signal."
datetime: "2026-07-07T02:02:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291876769.md)
  - [en](https://longbridge.com/en/news/291876769.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291876769.md)
generator: "portal-rs"
---

# Top Intellia Executive Quietly Unloads a Chunk of Company Stock

New insider activity at Intellia Therapeutics ( (NTLA) ) has taken place on July 6, 2026.

Intellia Therapeutics’ Vice President and Chief Accounting Officer, Michael P. Dube, recently executed a sale of company stock, unloading 2,641 shares for a total transaction value of $44,315. This insider move offers investors fresh insight into executive-level trading activity within the biotech firm.

**Spark’s Take on NTLA Stock**

According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.

The score is held back primarily by weak financial performance (large ongoing losses, cash burn, and negative TTM gross profit), partially offset by favorable corporate catalysts (strong Phase 3 data and rolling BLA) and a moderately positive technical backdrop (price above key moving averages). Valuation remains less supportive due to losses and no indicated dividend.

To see Spark’s full report on NTLA stock,  
 click here. 

**More about Intellia Therapeutics**

**YTD Price Performance:** 95.33%

**Average Trading Volume:** 6,636,184

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $2.45B

### Related Stocks

- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)

## Related News & Research

- [Intellia CEO John M. Leonard disposes of USD 286,764 in common shares](https://longbridge.com/en/news/296824125.md)
- [Intellia Q2 2026 Earnings: Lonvo-z Moves Toward a BLA](https://longbridge.com/en/news/295103160.md)
- [Spruce Biosciences targets Q4 2026 BLA filing for TA-ERT in Sanfilippo syndrome type B after FDA meetings](https://longbridge.com/en/news/296784399.md)
- [Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of "Hold" by Analysts](https://longbridge.com/en/news/292167372.md)
- [What's Going On With Cerebras Stock on Monday?](https://longbridge.com/en/news/296782127.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**